Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
复制标题
博茨瓦纳替诺福韦-恩曲他滨-依非韦伦起始妊娠年龄对不良出生结局的影响。
DOI：
10.1093/jpids/piy006
复制
发表时间：
2018
影响因子：
3.2
通讯作者：
Shapiro,RogerL
中科院分区：
文献类型：
--
作者：
Zash,Rebecca;Rough,Kathryn;Jacobson,DeniseL;Diseko,Modiegi;Mayondi,Gloria;Mmalane,Mompati;Essex,Max;Petlo,Chipo;Lockman,Shahin;Makhema,Joseph;Shapiro,RogerL
在博茨瓦纳接受推荐的一线抗逆转录病毒治疗方案（替诺福韦-恩曲他滨-依法韦仑）的人类免疫缺陷病毒阳性妇女中，我们发现死产、新生儿死亡、早产/极早产或婴儿出生时小于或小于胎龄的风险未增加。在妊娠前1年内使用替诺福韦-恩曲他滨-依法韦仑治疗，早产风险比中晚期治疗开始时略有增加（校正风险比，1.33 [95%置信区间，1.04-1.70]）。
Among human immunodeficiency virus–positive women in Botswana on the recommended first-line antiretroviral therapy regimen, tenofovir-emtricitabine-efavirenz, initiated within the first or early second trimester, we found no increased risk of stillbirth, neonatal death, preterm/very preterm delivery, or the infant being born small or very small for gestational age. Treatment with tenofovir-emtricitabine-efavirenz <1 year before conception increased the risk of preterm delivery slightly over late-second-trimester treatment initiation (adjusted risk ratio, 1.33 [95% confidence interval, 1.04–1.70]).